Compare

Keros Therapeutics, Inc. vs Akebia Therapeutics, Inc. vs Schrodinger, Inc. vs Puma Biotechnology, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	Keros Therapeutics, Inc. KROS	Akebia Therapeutics, Inc. AKBA	Schrodinger, Inc. SDGR	Puma Biotechnology, Inc. PBYI
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	$244.06M	$236.20M	$255.87M	$228.37M
Revenue growth (YoY)	n/m	+47.5%	+23.3%	-0.9%
Gross margin	n/a	83.3% (computed)	55.7%	74.5% (computed)
Operating margin	27.7%	9.9%	-65.2%	16.3%
Net margin	35.7%	-2.3%	-40.4%	13.6%
Net income	$87.01M	-$5.34M	-$103.27M	$31.11M
EPS (Diluted)	$2.30	-$0.02	-$1.41	$0.61
Operating cash flow	$107.50M	$67.99M	$13.90M	$41.80M
Free cash flow	$105.95M	$67.70M	$12.46M	$41.73M
Cash & equivalents	$287.42M	$184.84M	$230.52M	$29.64M
Total assets	$338.02M	$376.56M	$726.16M	$216.30M
Total liabilities	$34.89M	$343.95M	$362.11M	$85.96M
Shareholders' equity	$303.13M	$32.61M	$364.05M	$130.34M
Return on year-end equity	28.7%	-16.4%	-28.4%	23.9%
Shares outstanding	19.54M	265.42M	n/a	50.41M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	Keros Therapeutics, Inc.	Akebia Therapeutics, Inc.	Schrodinger, Inc.	Puma Biotechnology, Inc.
Latest	$244.06M Ended 2025-12-31	$236.20M Ended 2025-12-31	$255.87M Ended 2025-12-31	$228.37M Ended 2025-12-31
1 year earlier	$3.55M Ended 2024-12-31	$160.18M Ended 2024-12-31	$207.54M Ended 2024-12-31	$230.47M Ended 2024-12-31
2 years earlier	$151.0K Ended 2023-12-31	$194.62M Ended 2023-12-31	$216.67M Ended 2023-12-31	$235.64M Ended 2023-12-31
3 years earlier	$0 Ended 2022-12-31	$292.48M Ended 2022-12-31	$180.96M Ended 2022-12-31	$228.03M Ended 2022-12-31
4 years earlier	$20.10M Ended 2021-12-31	$211.65M Ended 2021-12-31	$137.93M Ended 2021-12-31	$253.16M Ended 2021-12-31